Treatment Outcomes and Plasma Level of Ritonavir-boosted Lopinavir Monotherapy Among HIV-infected Patients Who Had Non-nucleoside Reverse Transcriptase Inhibitor (NRTI) and NNRTI Failure: A Pilot Study

NCT01002898 Phase 3 COMPLETED

To assess 48-week treatment responses, tolerability, and steady-state minimum plasma concentrations of ritonavir-boosted lopinavir monotherapy for salvage therapy in HIV-1 infected patients who failed antiretroviral regimens containing NRTI and NNRTI.

Details

Lead sponsor	Bamrasnaradura Infectious Diseases Institute
Phase	Phase 3
Status	COMPLETED
Enrolment	40
Start date	2007-04
Completion	2011-02

Conditions

• HIV

Interventions

• lopinavir/ritonavir soft gel capsule

Primary outcomes

• To assess 48-week treatment responses of ritonavir-boosted lopinavir (LPV/r) monotherapy as salvage regimen. — 48 weeks

Countries

Thailand